MTFC yields 1.58% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, MTFC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MTFC + ABBV for your $10,000?
Minster Financial Corp. operates as a holding company for Minster Bank that provides various banking products and services for individuals, families, and businesses. It offers checking, savings, and money market products; certificates of deposits; and health savings and individual retirement accounts. The company also provides conventional fixed rate mortgages, adjustable rate mortgages, home construction and renovation loans, home equity and home improvement loans, home equity lines of credit, residential lot loans, government loans, and 1-4 family investment property loans; and commercial and agriculture real estate loans, equipment financing services, working capital lines of credit, construction loans, development loans, and SBA/USDA loans. In addition, it offers cash management, online and mobile banking, and bill pay services; merchant, payroll, and retirement plan solutions; debit and credit cards; and overdraft protection, direct deposit, and safe deposit services. Further, the company provides wealth planning, investment management, retirement plan, and trust services; and brokerage services for stocks, bonds, mutual funds, annuities, and brokered CDs, as well as insurance agency services. Minster Financial Corp. was founded in 1914 and is based in Minster, Ohio.
Full MTFC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.